alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99.1

                    GE GLOBAL INSURANCE HOLDING CORPORATION
                          AND CONSOLIDATED SUBSIDIARIES


                           CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of GE Global Insurance Holding  Corporation
(the "Company") on Form 10-K for the year ended December 31, 2002, as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
Ronald R. Pressman, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to my knowledge:

     (1) The Report fully  complies  with the  requirements  of section 13(a) or
         15(d) of the Securities Exchange Act of 1934; and

     (2) The  information  contained  in the  Report  fairly  presents,  in  all
         material respects, the financial condition and  result of operations of
         the Company.






  /s/ Ronald R. Pressman
--------------------------
Ronald R. Pressman
Chief Executive Officer
March 7, 2003



                                       76
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 99-31402

Summary Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

CEMUEL HENDERSON,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Eastern District of Louisiana

USDC No. 99-CR-39-ALL-K

--------------------

September 14, 2000

Before JOLLY, DAVIS, and STEWART, Circuit Judges.

PER CURIAM:*

Cemuel Henderson challenges the sentence he received

following his guilty-plea conviction for being a felon in

possession of a firearm, in violation of 18 U.S.C. § 922(g). He

argues that the district court erred in imposing a four-level

increase, pursuant to U.S.S.G. § 2K2.1(b)(5), for possessing the

firearm in connection with another felony offense, possession of

drugs, because his possession of the gun was merely incidental to

his possession of the drugs. Henderson does not renew his

argument that the Supreme Court’s decision in Bailey v. United
No. 99-31402

-2-

States, 516 U.S. 127 (1995), should be interpreted to mean that

the “mere proximity” of drugs and weapons is insufficient to

establish a relationship between the two under § 2K2.1(b)(5), and

the argument is therefore waived. See id. at 6-9; see also Yohey

v. Collins, 985 F.2d 222, 224-25 (5th Cir. 1993)(arguments not

briefed on appeal are deemed abandoned); Fed. R. App. P.

28(a)(9). 

The district court did not err in applying the four-point

enhancement in the instant case because the gun Henderson

possessed was found in close physical proximity to the drugs he

possessed and was readily available to him to protect his drug

possession. The gun was thus possessed “in connection with”

Henderson’s felony drug possession within the meaning of 

§ 2K2.1(b)(5). See United States v. Condren, 18 F.3d 1190, 1199-

2000 (5th Cir. 1994). Henderson’s attempts to distinguish

Condren are without merit, and his argument that this court

should reject Condren in favor of the Ninth Circuit’s more

stringent approach is unavailing. See Hogue v. Johnson, 131 F.3d

466, 491 (5th Cir. 1997).

AFFIRMED.
§ 310.502 Certain drugs accorded new drug status through rulemaking procedures. ( a ) The drugs listed in this paragraph (a) have been determined by rulemaking procedures to be new drugs within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act. An approved new drug application under section 505 of the Federal Food, Drug, and Cosmetic Act and part 314 of this chapter is required for marketing the following drugs: ( 1 ) Aerosol drug products for human use containing 1,1,1-trichloroethane.
( 2 ) Aerosol drug products containing zirconium.
( 3 ) Amphetamines (amphetamine, dextroamphetamine, and their salts, and levamfetamine and its salts) for human use.
( 4 ) Camphorated oil drug products.
( 5 ) Certain halogenated salicylanilides (tribromsalan (TBS, 3,4′,5-tribromosalicylanilide), dibromsalan (DBS, 4′, 5-dibromosalicylanilide), metabromsalan (MBS, 3, 5-dibromosalicylanilide), and 3,3′, 4,5′-tetrachlorosalicylanilide (TC-SA)) as an ingredient in drug products.
( 6 ) Chloroform used as an ingredient (active or inactive) in drug products.
( 7 ) Cobalt preparations intended for use by man.
( 8 ) Intrauterine devices for human use for the purpose of contraception that incorporate heavy metals, drugs, or other active substances.
( 9 ) Oral prenatal drugs containing fluorides intended for human use.
( 10 ) Parenteral drug products in plastic containers.
( 11 ) [Reserved]
( 12 ) Sweet spirits of nitre drug products.
( 13 ) Thorium dioxide for drug use.
( 14 ) Timed release dosage forms.
( 15 ) Vinyl chloride as an ingredient, including propellant, in aerosol drug products.
( b ) [Reserved]
[62 FR 12084, Mar. 14, 1997, as amended at 64 FR 401, Jan. 5, 1999; 84 FR 68334, Dec. 16, 2019]
[No. 39743-5-I.

Division One.

November 17, 1997.]

#### The State of Washington, *Respondent,*v. C.B., *Appellant.*

Appeal from a judgment of the Superior Court for What-com County, No. 96-8-00641-4, Charles Snyder, J. Pro Tern., entered October 30, 1996. *Affirmed*by unpublished opinion per Ellington, J., concurred in by Agid and Cox, JJ.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7666 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7666

   To require the Secretary of Agriculture to develop a strategy to 
   increase opportunities to utilize livestock grazing as a means of 
                        wildfire risk reduction.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 13, 2024

  Mr. LaMalfa (for himself and Mr. Vasquez) introduced the following 
   bill; which was referred to the Committee on Agriculture, and in 
  addition to the Committee on Natural Resources, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL

 
   To require the Secretary of Agriculture to develop a strategy to 
   increase opportunities to utilize livestock grazing as a means of 
                        wildfire risk reduction.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. UTILIZING GRAZING FOR WILDFIRE RISK REDUCTION.

    The Secretary of Agriculture, acting through the Chief of the U.S. 
Forest Service, in coordination with holders of permits to graze 
livestock on Federal land, shall develop a strategy to increase 
opportunities to utilize livestock grazing as wildfire risk reduction 
strategy, including--
            (1) completion of reviews (as required under the National 
        Environmental Policy Act of 1969 (U.S.C. 4321 et seq.)) to 
        allow permitted grazing on vacant grazing allotments during 
        instances of drought, wildfire or other natural disasters that 
        disrupt grazing on allotments already permitted;
            (2) use of targeted grazing;
            (3) increase use of temporary permits to promote targeted 
        fuels reduction and reduction of invasive annual grasses;
            (4) increased use of grazing as a postfire recovery and 
        restoration strategy, where appropriate; and
            (5) use all applicable authorities under the law.
                                 <all>
```
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4360 Nonroller-type blood pump. ( a ) *Nonroller-type cardiopulmonary and circulatory bypass blood pump* — ( 1 ) *Identification.* A nonroller-type cardiopulmonary and circulatory bypass blood pump is a prescription device that uses a method other than revolving rollers to pump the blood through an extracorporeal circuit for periods lasting less than 6 hours for the purpose of providing either: ( i ) Full or partial cardiopulmonary bypass (*i.e.,* circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or
( ii ) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.
( 2 ) *Classification* —Class II (special controls). The special controls for this device are: ( i ) Non-clinical performance testing must perform as intended over the intended duration of use and demonstrate the following: Operating parameters, dynamic blood damage, heat generation, air entrapment, mechanical integrity, and durability/reliability;
( ii ) The patient-contacting components of the device must be demonstrated to be biocompatible;
( iii ) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components; and
( iv ) Labeling must include information regarding the duration of use, and a detailed summary of the device- and procedure-related complications pertinent to use of the device.
( b ) *Nonroller-type temporary ventricular support blood pump* — ( 1 ) *Identification.* A nonroller-type temporary ventricular support blood pump is a prescription device that uses any method resulting in blood propulsion to provide the temporary ventricular assistance required for support of the systemic and/or pulmonary circulations during periods when there is ongoing or anticipated hemodynamic instability due to immediately reversible alterations in ventricular myocardial function resulting from mechanical or physiologic causes. Duration of use would be less than 6 hours.
( 2 ) *Classification.* Class III (premarket approval).
( c ) *Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required.* A PMA or notice of completion of a PDP is required to be filed with FDA on or before September 8, 2015, for any nonroller-type temporary ventricular support blood pump that was in commercial distribution before May 28, 1976, or that has, on or before September 8, 2015, been found to be substantially equivalent to any nonroller-type temporary ventricular support blood pump that was in commercial distribution before May 28, 1976. Any other nonroller-type temporary ventricular support blood pump shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[80 FR 32311, June 8, 2015]
**Exhibit32.1**

**CERTIFICATIONPURSUANT TO**

**18 U.S.C.SECTION 1350,**

**ASADOPTED PURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

In connection with theQuarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the periodended September 30, 2006 as filed with the Securities and Exchange Commissionon the date hereof (the “Report”), I, Robin Raina, Chief Executive Officer ofthe Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 ofthe Sarbanes-Oxley Act of 2002, that:

1. The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2. The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.
| By:                     | /s/ Robin Raina |   |
|-------------------------|-----------------|--------|
|                    |            |   |
| Name:                   | Robin Raina     |   |
|                    |            |   |
| Chief Executive Officer |            |
|                    |            |   |
| November 20, 2006       |            |

 

----
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1647 Copper powder. ( a ) *Identity.* ( 1 ) The color additive copper powder is a very fine free-flowing metallic powder prepared from virgin electrolytic copper. It contains small amounts of stearic or oleic acid as lubricants.
( 2 ) Color additive mixtures for drug use made with copper powder may contain only those diluents listed in this subpart as safe and suitable for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* Copper powder shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Stearic or oleic acid, not more than 5 percent. Cadmium (as Cd), not more than 15 parts per million. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Copper (as Cu), not less than 95 percent. Maximum particle size 45μ (95 percent minimum).
( c ) *Uses and restrictions.* Copper powder may be safely used in coloring externally applied drugs, including those intended for use in the area of the eye, in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The color additive and any mixture prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of the color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[42 FR 33723, July 1, 1977]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5860 Total spinal fluid immunological test system. ( a ) *Identification.* A total spinal fluid immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the total protein in cerebrospinal fluid. Measurement of spinal fluid proteins may aid in the diagnosis of multiple sclerosis and other diseases of the nervous system.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38793, July 25, 2001]
Exhibit 10.2


 


Amendment #2 to Sponsored Research Agreement


 


This Amendment #2 to Sponsored Research Agreement (this “Amendment
#2”), executed on November 12, 2014 (“Agreement”), is made and entered into as of November 30, 2016 (“Amendment
#2 Effective Date”) by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital
of Philadelphia (“CHOP”).


 


RECITALS


Whereas SPONSOR and CHOP desire to amend the Sponsored Research
Agreement to extend the term of the Agreement and to increase the Budget of the Research Program by $6,455,772 for a new total
of $17,263,325.


 


Whereas any capitalized term not separately defined in this Amendment
#2 shall have the meaning ascribed to it in the Agreement.


 


Now, therefore, in consideration of the mutual agreements, promises
and covenants contained herein SPONSOR and CHOP hereby agree to amend the Sponsored Research Agreement as follows:


 


		1.	Section 3.1 of the Agreement is hereby replaced in its entirety with the following:



“Term. The term of this AGREEMENT shall begin on
the EFFECTIVE DATE and shall end on June 30, 2018. This AGREEMENT may be extended or renewed beyond June 30, 2018, only with the
PARTIES’ mutual written agreement.”


 


		2.	Invoice and Payment Schedule of Attachment B (Budget) as
attached to Amendment #1 to Sponsored Research Agreement dated December 18, 2015, is hereby supplemented by Attachment B to this
Amendment #2 and thus the statement of work and budget for Phase 3 is authorized through June 30, 2018.



 




All other terms and conditions of the Sponsored Research Agreement
not amended herein shall remain in full force and effect.


 


In witness whereof, SPONSOR and CHOP have caused this Amendment
#2 to be duly executed as of the Amendment #2 Effective Date.


 


	MEDGENICS MEDICAL ISRAEL, LTD.	 	THE CHILDREN’S HOSPITAL OF PHILADELPHIA
	By:	 	 	By:	 
	Name:	Michael Cola	 	Name:	Prema Sundaram  
	Title:	Chief Executive Officer	 	Title:	Manager, Sponsored Projects
	Date:	 	 	Date:	 


 


	AGREED AND ACKNOWLEDGED	 
	BY:	 	 
	Name:	Hakon Hakonarson, MD	 
	Title:	Principal Investigator, Director, CAG	 
	Date:
# C_2014052EN.01005101.xml

| 22.2.2014 | EN | Official Journal of the European Union | C 52/51 |
| --- | --- | --- | --- |

22.2.2014

EN

Official Journal of the European Union

C 52/51

---

Action brought on 3 January 2014 — Inditex and Naviera Nebulosa de Omega v Commission

(Case T-10/14)

2014/C 52/99

Language of the case: Spanish

Parties

Parties

Applicants: Industria de Diseño Textil, SA (Inditex) (Arteixo, Spain) and Naviera Nebulosa de Omega, AIE (Las Palmas de Gran Canaria, Spain) (represented by: J.L. Buendía Sierra, E. Abad Valdenebro, R. Calvo Salinero, A. Lamadrid de Pablo and A. Biondi, lawyers)

Applicants:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicants claim that the General Court should:

| — | annul the contested decision in so far as it categorises the measures which, according to that decision, together constitute the ‘Spanish Tax Lease System’ as new State aid that is incompatible with the internal market; |
| --- | --- |

—

annul the contested decision in so far as it categorises the measures which, according to that decision, together constitute the ‘Spanish Tax Lease System’ as new State aid that is incompatible with the internal market;

| — | in the alternative, annul Articles 1 and 4 of the contested decision, which identify the investors in the Economic Interest Groupings (EIGs) as beneficiaries of the alleged aid and as the sole addressees of the order for recovery; |
| --- | --- |

—

in the alternative, annul Articles 1 and 4 of the contested decision, which identify the investors in the Economic Interest Groupings (EIGs) as beneficiaries of the alleged aid and as the sole addressees of the order for recovery;

| — | in the alternative, annul Article 4 of the contested decision, in so far as it orders recovery of the alleged aid; |
| --- | --- |

—

in the alternative, annul Article 4 of the contested decision, in so far as it orders recovery of the alleged aid;

| — | annul Article 4 of the contested decision, in so far as it makes a determination as to the lawfulness of the private contracts between the investors and other entities; and |
| --- | --- |

—

annul Article 4 of the contested decision, in so far as it makes a determination as to the lawfulness of the private contracts between the investors and other entities; and

| — | order the Commission to pay the costs of these proceedings. |
| --- | --- |

—

order the Commission to pay the costs of these proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments are those put forward in Case T-700/13 Bankia v Commission.

Bankia

Commission

---
Michigan Supreme Court Lansing, Michigan

Stephen J. Markman

, Chief Justice

Brian K. Zahra Bridget M. McCormack

David F. Viviano

Richard H. Bernstein Joan L. Larsen Kurtis T. Wilder,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

June 27, 2017

d0619t 

# Order

Clerk June 27, 2017

154425

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff

- Appellee,

v SC: 154425 COA: 331774 Macomb CC: 2009

- 005130

- FC; DUNCAN LORENZO ALEXANDER, 2009

- 005132

- FC; Defendant

- Appellant. 2009

- 005135

- FC

_________________________________________/

On order of the Court, the application for leave to appeal the July 25, 2016 order of the Court of Appeals is considered and, pursuant to MCR 7.305(H)(1), in lieu of granting leave to appeal, we VACATE the December 17, 2015 opinion and order of the Macomb Circuit Court, which denied relief from judgment under MCR 6.502(G), and we

REMAND this case to the circuit c ourt for reconsideration. The defendant’s motion for a new trial and DNA testing sought relief under MCL 770.16 rather than under MCR 6.508(D). Moreover, the motion was filed with regard to case 2009

- 005130

- FC only, as

shown on the circuit court’s March 2, 2015 opinion and order denying relief. Under the circumstances, the defendant’s subsequent motion for relief from judgment, filed with regard to cases 2009

- 005130

- FC, 2009

- 005132

- FC, and 2009

- 005135

- FC, is not barred by MCR 6.502(G). On remand, the tr ial court shall review the defendant’s motion for relief from judgment under the standard set forth in MCR 6.508(D).

We do not retain jurisdiction.

W ILDER , J., did not participate because he was on the Court of Appeals panel.
<PAGE>   1
THE LOEWEN GROUP INC.

(NYSE, TSE, ME: LWN)
NEWS


Contact:       Sitrick And Company
                      Michael Kolbenschlag
               Brenda Adrian
               (604) 293-6483 or
               (310) 788-2850

                              FOR IMMEDIATE RELEASE

   LOEWEN GROUP ANNOUNCES RESIGNATION OF THOMAS TAYLOR FROM BOARD OF DIRECTORS

                                  -------------

Vancouver, B.C., June 1, 1999 - THE LOEWEN GROUP INC. (NYSE,TSE,ME:LWN)
confirmed today the resignation of Thomas Taylor as a director of the Company.
Mr. Taylor, who was also a significant shareholder in the Company, joined the
Loewen Board in December of 1998.

"I'm sad to see Tom go," said John Lacey, Loewen Group chairman. "But I fully
understand his decision to resign now that the Company has filed for a
reorganization which will ultimately change his holdings in the Company."

Mr. Lacey continued, "Tom and I joined the board together and, as a significant
shareholder, he was an important resource for the Company. He did an outstanding
job and always put the Company's best interests ahead of his own personal
holdings. For that I will always be grateful and deeply appreciative. On behalf
of the entire Loewen Group board, I wish him well."

Mr. Lacey added that candidates for the seat vacated by Mr. Taylor will be
discussed at this week's governance committee meeting of the Board.

Based in Vancouver, The Loewen Group Inc. owns or operates more than 1100
funeral homes and more than 400 cemeteries across the United States, Canada and
the United Kingdom. The Company employs approximately 13,000 people and derives
90 percent of its revenue from U.S. operations.


<PAGE>   2
Safe Harbor: Certain statements contained in this press release, including but
not limited to information regarding the future economic performance and
financial condition of the Company, the plans and objectives of the Company's
management and the Company's assumptions regarding such performance and plans,
are forward-looking in nature. Additional information concerning important
factors that could cause actual results to differ from the forward-looking
information contained in this release is included in the Company's publicly
filed quarterly and annual reports.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3320 Digoxin test system. ( a ) *Identification.* A digoxin test system is a device intended to measure digoxin, a cardiovascular drug, in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of digoxin overdose and in monitoring levels of digoxin to ensure appropriate therapy.
( b ) *Classification.* Class II.